Partnership Helps Labs Transform Raw Genetic Testing Data into Actionable Reports
San Diego, Calif., -- July 28, 2015 -- XIFIN, Inc., the healthcare cloud computing company revolutionizing the business of healthcare diagnostics from patient to payment, today announced it has entered into an agreement with Translational Software®, a leader in integrating genetic information into routine clinical care, to market its end-to-end pharmacogenetic (PGx) knowledge solutions to support customers involved in PGx testing and personalized medicine initiatives.
XIFIN will make Translational Software’s knowledgebase and interpretation platform available via its laboratory information system, XIFIN LIS, to molecular diagnostic laboratories seeking guidance in interpreting raw genetic test results to determine the most effective patient treatments. Powered by the company’s Health Economics Optimization platform to facilitate the open and secure exchange of diagnostic financial and clinical information, the partnership provides a complete and seamless PGx solution including test ordering and interpretation, laboratory workflow management, PGx-tailored reporting, billing and financial management.
With the continuing evolution of precision medicine and the growing complexity of new clinical and molecular diagnostic tests, it is increasingly difficult for clinicians to stay current with the latest information driving effective treatment decisions. As outlined in its new white paper, “A Lab Leader’s Guide to Pharmacogenomic Testing,” Translational Software highlights the challenges associated with analyzing and interpreting the complex mix of raw data that PGx testing generates, and the struggle to turn the information into meaningful intelligence to help improve patient treatment.
Don Rule, Translational Software’s founder and CEO stated, “XIFIN’s in-depth experience and understanding of the needs of high-growth molecular diagnostic companies make them an ideal partner as we continue to expand our knowledge solutions to make genetic testing an efficient and cost-effective tool for clinicians. We are pleased to be part of an integrated solution that helps leading labs link a patient’s genetic make-up to specific clinical guidance.”
The Translational Software platform automates the reporting process by matching test results to a knowledgebase of evidence for clinical genetics. The knowledgebase includes treatment guidelines based on curated data gathered from consortia and professional society recommendations, regulatory filings, literature review and other sources. The report focuses on genetic factors that affect the efficacy and toxicity of many drugs as well as risk factors relevant to the patient’s health in order to guide clinical decision making.
“Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market, and new targeted therapies are continually in development,” stated Lâle White, CEO of XIFIN. “Our partnership with Translational Software will be instrumental in helping XIFIN fulfill its mission to improve the accuracy of laboratory test selection and result interpretation and support the information exchange needed for value-based healthcare initiatives. In addition, Translational’s interpretation solutions will accelerate our customer’s ability to bring new genetic tests to market quickly, pursue the most effective patient therapies and improve operating efficiency.”
About Translational Software
Translational Software provides end-to-end solutions to support physicians adopting personalized medicine. Its powerful PGx Portal is an advanced, cloud-based solution providing clients with access to the company’s proprietary knowledgebase. Coupled with advanced laboratory molecular data, it generates HIPAA-compliant reports for referring clinicians with easy-to-understand recommendations and guidance on therapeutic options for patients’ medication management. For more information visit www.translationalsoftware.com